MEIS1 (Myeloid Ecotropic Viral Integration Site 1) antibody is a key reagent used to detect and study the MEIS1 protein, a transcription factor belonging to the TALE (Three-Amino acid Loop Extension) family. MEIS1 plays critical roles in embryonic development, hematopoiesis, and neuronal differentiation. It interacts with HOX and PBX proteins to regulate gene expression, influencing cell proliferation, differentiation, and tissue patterning. In hematopoietic stem cells, MEIS1 is essential for maintaining self-renewal capacity, while in the nervous system, it contributes to neurogenesis and dopaminergic neuron development.
Dysregulation of MEIS1 is implicated in various cancers, particularly acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL), where its overexpression often correlates with poor prognosis. It is also associated with solid tumors, such as prostate cancer and neuroblastoma. MEIS1 antibodies are widely utilized in research to investigate these mechanisms via techniques like immunohistochemistry, Western blotting, and ChIP-seq. Additionally, MEIS1 has emerged as a potential therapeutic target, driving interest in developing inhibitors.
Commercially available MEIS1 antibodies are typically validated for specificity in human, mouse, and rat models. Their applications span basic research on developmental pathways, disease biomarker studies, and drug discovery. Understanding MEIS1’s role through antibody-based assays continues to advance insights into both normal physiology and oncogenesis.